Clinical Trial Update: Harvard Atherosclerosis Reversibility Project (HARP) [Phase 2]

View source ↗

Summary

Phase 2 trial update for the Harvard Atherosclerosis Reversibility Project (HARP). The study status is Completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Coronary Artery Disease
• Myocardial Ischemia

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Cardiovascular Diseases, Coronary Disease | Phase 2 | Status: COMPLETED